C

CanadaBis Capital Inc
XTSX:CANB

Watchlist Manager
CanadaBis Capital Inc
XTSX:CANB
Watchlist
Price: 0.025 CAD Market Closed
Market Cap: 3.5m CAD

Relative Value

CANB doesn't have a meaningful market cap.

The Relative Value of one CANB stock under the Base Case scenario is hidden CAD. Compared to the current market price of 0.025 CAD, CanadaBis Capital Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CANB Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
74
Median 3Y
0.6
Median 5Y
0.7
Industry
2.7
vs History
vs Industry
6
Median 3Y
8.6
Median 5Y
5.3
Industry
21.6
vs History
vs Industry
38
Median 3Y
-2
Median 5Y
-4.3
Industry
16.9
vs History
vs Industry
32
Median 3Y
-4.2
Median 5Y
-5.4
Industry
22.9
vs History
98
vs Industry
45
Median 3Y
1.3
Median 5Y
3
Industry
2.3
vs History
85
vs Industry
69
Median 3Y
0.9
Median 5Y
1
Industry
3
vs History
77
vs Industry
67
Median 3Y
1.8
Median 5Y
2
Industry
5.6
vs History
14
vs Industry
25
Median 3Y
7.8
Median 5Y
5.1
Industry
13.4
vs History
4
vs Industry
9
Median 3Y
11.3
Median 5Y
6.9
Industry
16.7
vs History
vs Industry
30
Median 3Y
-3.3
Median 5Y
-5.9
Industry
16.1
vs History
vs Industry
5
Median 3Y
-3.1
Median 5Y
-5.7
Industry
18.9
vs History
88
vs Industry
50
Median 3Y
1
Median 5Y
1
Industry
2

Multiples Across Competitors

CANB Competitors Multiples
CanadaBis Capital Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
CanadaBis Capital Inc
XTSX:CANB
3.5m CAD 0.2 -2.7 9.9 66.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 109 159.5
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
CA
C
CanadaBis Capital Inc
XTSX:CANB
Average P/E: 24.9
Negative Multiple: -2.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
C
CanadaBis Capital Inc
XTSX:CANB
Average EV/EBITDA: 400.9
9.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
C
CanadaBis Capital Inc
XTSX:CANB
Average EV/EBIT: 1 718.4
66.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.5
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5